Biogen exchange offer
We advised the dealer managers on a debt exchange offer
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Oak Street Health $600.5 million secondary offering
We advised the joint book-running managers on the equity offering
Signify Health $648.6 million IPO
We advised Signify Health on its IPO and NYSE listing
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Bolt Biotherapeutics $230 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Terns Pharmaceuticals $127.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Revolution Medicines $300 million follow-on offering
We advised the underwriters in connection with the equity offering
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Venus Medtech HK$1.4 billion placing of new H shares
We advised Venus Medtech (Hangzhou) on its placement of new shares